A balding man watches snow fall on trees.

Melancholia is a severe subtype of depression characterized by profound despair, complete loss of pleasure, and distinct physical symptoms. People with melancholic depression experience a qualitatively different mood state that goes beyond typical sadness, often accompanied by significant guilt and psychomotor changes.

Although melancholic depression can be challenging to treat, recovery is possible with appropriate interventions. Mental health professionals can help individuals with melancholia through evidence-based treatments tailored to this specific depression subtype.

Table of Contents

  • History of Melancholia
  • What Is Melancholia?
  • Diagnostic Criteria and Features
  • Melancholia vs Other Types of Depression
  • Causes and Risk Factors
  • Neurobiological Features
  • Effects and Impact
  • Treatment Approaches
  • Getting Help
  • Frequently Asked Questions

History of Melancholia

The concept of melancholia has evolved significantly throughout history. In 400 B.C., the Greek philosopher Hippocrates theorized that the human body contained four major fluids: blood, black bile, yellow bile, and phlegm. An excess of black bile was believed to cause someone to become despondent and fearful. The Greeks called this condition melancholia, making it the first recorded term for depression.

During the Renaissance, Europeans viewed melancholia as a sign of creative genius, glorifying it through art, fashion, and literature. However, by the 18th century, the term returned to its clinical roots. In the 19th century, people began using "depression" synonymously with melancholia.

Sigmund Freud's influential 1917 work, On Murder, Mourning and Melancholia, helped modernize the concept into its current clinical understanding, distinguishing pathological grief from normal mourning processes.

What Is Melancholia?

Today, melancholia is classified in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, text revision (DSM-5-TR) as a specifier for major depressive disorder rather than a standalone condition. Individuals receive a diagnosis of major depressive disorder (MDD) with melancholic features. Melancholia can also occur during the depressive phase of bipolar disorder.

The specifier "with melancholic features" is used if these features are present at the most severe stage of the episode. Melancholy means there is a near-complete absence of the capacity for pleasure, not just diminished pleasure. This distinction is crucial for accurate diagnosis and treatment planning.

Diagnostic Criteria and Features

According to the DSM-5-TR, to be diagnosed with melancholic depression, a person must present at least one of these symptoms:

  • Loss of enjoyment from all (or nearly all) activities
  • Lack of positive response to objectively pleasurable events

And at least three of the following:

  • Despair with a distinct quality, different from typical grief or sadness
  • Significant weight loss or loss of appetite
  • Psychomotor changes: Either physical restlessness or slowed movement
  • Diurnal mood variation: Depression worse in the morning
  • Early-morning awakening (at least 2 hours before normal)
  • Excessive or inappropriate guilt

The "distinct quality" of mood that is characteristic of the "with melancholic features" specifier is experienced as qualitatively different from that during a non-melancholic depressive episode. A depressed mood that is described as merely more severe, longer lasting, or present without a reason is not considered distinct in quality.

Psychomotor changes are nearly always present and are observable by others. These changes represent one of the hallmark features distinguishing melancholic from non-melancholic depression.

Melancholia vs Other Types of Depression

Melancholic depression differs significantly from other depression subtypes:

Key Differences:

Melancholic patients (16.2%) were more severely depressed, had more depressive episodes and shorter episode duration than atypical (24.7%) and non-melancholic patients.

Compared to individuals with other depression types, those with melancholia typically:

  • Develop symptoms at a later age
  • Experience more severe symptoms, including complete inability to feel happiness
  • Show more prominent psychomotor symptoms
  • Have higher rates of anxiety and suicidal thoughts
  • Experience shorter episodes that are more episodic in nature, with diurnal variation featuring early-morning worsening of mood

Females are less affected in melancholic depression, and there is typically an older age of onset, contrasting with general depression patterns where women are more commonly affected.

Causes and Risk Factors

Melancholic depression is considered to be a more "biologically-based" depression. Unlike other depression subtypes where psychological and social factors play major roles, melancholia appears to have stronger biological underpinnings.

Genetic Factors

Individuals often have hypercortisolemia and there is a strong genetic and familial association in melancholic depression. People with melancholia are likely to have a family history of mood disorders or suicide.

Biological Mechanisms

Research suggests several biological differences in melancholic depression:

  • Altered hypothalamic-pituitary-adrenal (HPA) axis function
  • Differences in neural connectivity, particularly involving the insula
  • Changes in neurotransmitter systems

Some studies found that melancholic patients initially present with high levels of severity and may respond less well to SSRI treatment than to venlafaxine or tricyclic antidepressants, suggesting distinct neurobiological pathways.

Neurobiological Features

Several biological changes occur more frequently in melancholia than in other forms of depressive illness. Three indicative markers are known: Hypercortisolemia, reflected in the dexamethasone suppression test (DST), which is common in melancholia and relatively uncommon in nonmelancholic mood disorders; Psychomotor disturbance measurable by the CORE scale, with CORE scores demonstrating a linear relationship with DST nonsuppression rates; and characteristic disturbances in sleep architecture, with reduced REM latency, increased REM time, and reduced deep sleep.

Brain Structure and Function

People with melancholia may have:

  • Fewer neurons connecting to their insula (responsible for attention and self-awareness)
  • Altered functioning of the hypothalamus, pituitary gland, and adrenal glands
  • Disruption of the HPA axis

These neurobiological changes help explain the distinct symptom profile and treatment response patterns seen in melancholic depression.

Effects and Impact

Melancholia has profound effects on multiple aspects of functioning:

Physical Health

  • Elevated cortisol levels increasing stress response
  • Significant weight loss and appetite changes
  • Chronic inflammation
  • Disturbances in sleep architecture such as terminal insomnia
  • Reduced quality of rest despite spending time in bed

Cognitive Function

Research shows melancholia specifically impairs:

  • Working memory
  • Visual learning
  • Verbal learning
  • Problem-solving abilities
  • Executive functioning

Social and Occupational Impact

The severity of melancholic symptoms often leads to:

  • Significant impairment in work or school performance
  • Strained relationships
  • Social withdrawal and isolation
  • Increased risk of job loss or academic failure

Suicide Risk

Risk factors linked to TRD (treatment-resistant depression) include comorbidity (particularly anxiety and personality disorders), suicide risk, episode severity, number of hospitalizations, episode recurrence, early-onset, and melancholic features. Melancholia tends to cause longer periods of suicidal thinking than other depression types, making careful monitoring essential.

Treatment Approaches

Melancholic patients showed lower rates of remission. Our study supports a different clinical pattern and treatment outcome for melancholic and atypical depression subtypes.

Medication Options

Melancholic patients respond better to broad-action tricyclic antidepressants than to narrow-action antidepressants (e.g., serotonin uptake inhibitors). They respond well to ECT.

Current evidence suggests:

1. First-line medications:

  • Tricyclic antidepressants (TCAs)
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine
  • The adjusted 4-month probability of remission was 26.9% for melancholic and 53.8% for nonmelancholic patients receiving citalopram, showing lower SSRI effectiveness

1. Alternative approaches:

  • Ketamine has shown promise for treatment-resistant depression, with recent studies comparing it to ECT
  • Psilocybin therapy has been shown to have potential as a treatment for depression in almost 400 participants. Phase 3 trials starting in 2023 will further probe efficacy

Non-Pharmacological Treatments

1. Electroconvulsive Therapy (ECT)

  • Melancholic patients respond well to ECT
  • Often considered for severe or treatment-resistant cases
  • High response rates in melancholic depression

1. Psychotherapy

  • In comparison to those with nonmelancholic mood disorders, melancholic patients rarely respond to placebos, psychotherapies, or social interventions
  • However, therapy can be helpful as an adjunct to medication
  • Cognitive-behavioral therapy (CBT) may help with residual symptoms

1. Other Interventions

  • Repetitive transcranial magnetic stimulation (rTMS)
  • Light therapy (particularly for seasonal patterns)
  • Combined group exercise with antidepressants emerged as efficacious versus pill placebo

Treatment Considerations

Studies have shown that tools such as the Newcastle Scale or the Sydney Melancholia Prototype Index (SMPI) are more useful than the DSM melancholic features specifier for research purposes. The DSM specifier would identify severe depression rather than true melancholia.

Treatment planning should consider:

  • Severity of symptoms
  • Previous treatment response
  • Family history
  • Suicide risk assessment
  • Medical comorbidities
  • Patient preferences

Getting Help

If you or a loved one is experiencing symptoms of melancholic depression, seeking professional help is crucial. Given the biological nature of this condition and its resistance to psychotherapy alone, medical evaluation is particularly important.

Steps to Take:

1. Contact a mental health professional specializing in mood disorders

2. Get a comprehensive evaluation including medical history and family history

3. Discuss all treatment options including medication, ECT, and emerging therapies

4. Create a safety plan if experiencing suicidal thoughts

5. Involve trusted family or friends in your treatment journey

Remember that melancholic depression, while severe, is treatable. SAMHSA is committed to promoting the prevention, treatment, and recovery for those who have serious mental illness. Recovery is possible with appropriate treatment and support.

Crisis Resources:

  • 988 Suicide & Crisis Lifeline: Call or text 988
  • Crisis Text Line: Text HOME to 741741
  • SAMHSA National Helpline: 1-800-662-4357

Frequently Asked Questions

How is melancholic depression different from regular depression?

Melancholic depression involves a complete inability to experience pleasure, distinct mood quality different from sadness, prominent physical symptoms like psychomotor changes, and typically worse symptoms in the morning. It's considered more biologically based and often requires different treatment approaches than other depression types.

What treatments work best for melancholic depression?

Research shows melancholic patients respond better to broad-action tricyclic antidepressants than to narrow-action antidepressants like SSRIs. ECT is highly effective for severe cases. Newer treatments like ketamine are showing promise for treatment-resistant cases.

Can melancholic depression be cured?

While melancholic depression is a serious condition, it is treatable. Many people achieve full remission with appropriate treatment, though some may need ongoing maintenance therapy to prevent recurrence. Melancholic features have only a modest tendency to repeat across episodes in the same individual.

Is melancholic depression genetic?

Yes, there is a strong genetic and familial association in melancholic depression. Having family members with mood disorders increases your risk, though environmental factors also play a role.

Why do I feel worse in the morning?

Diurnal mood variation is a hallmark of melancholic depression, featuring early-morning worsening of mood. This pattern is related to circadian rhythm disruptions and cortisol level changes typical of this condition.

Should I try therapy or medication first?

Research shows melancholic patients rarely respond to psychotherapies alone. Most experts recommend starting with medication, possibly combined with supportive therapy. Your treatment team can help determine the best approach for your specific situation.

How Therapy Can Help / Find a Therapist

While melancholic depression often requires biological treatments, working with a qualified mental health professional is essential for comprehensive care. A therapist can:

  • Help monitor your symptoms and treatment response
  • Provide support during the recovery process
  • Teach coping strategies for residual symptoms
  • Address any co-occurring conditions
  • Support family members affected by your condition

[Find a therapist near you](https://www.goodtherapy.org/find-therapist.html) who specializes in mood disorders and has experience treating melancholic depression. Look for professionals who:

  • Understand the biological nature of melancholic depression
  • Can coordinate with psychiatrists for medication management
  • Have experience with severe depression cases
  • Use evidence-based approaches

Remember, reaching out for help is a sign of strength, not weakness. With proper treatment, people with melancholic depression can recover and return to fulfilling lives.

References:

  1. [Find a therapist near you](https://www.goodtherapy.org/find-therapist.html) who specializes in mood disorders and has experience treating melancholic depression. Look for professionals who:
  2. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
  3. American Psychological Association. (2019, updated 2024). Clinical practice guideline for the treatment of depression across three age cohorts. Retrieved from https://www.apa.org/depression-guideline
  4. Anand, A., Mathew, S. J., Sanacora, G., et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 388, 2315-2325. https://doi.org/10.1056/NEJMoa2302399
  5. Centers for Disease Control and Prevention. (2024). Mental Health Data Channel. Retrieved from https://www.cdc.gov/mental-health/about-data/index.html
  6. Chen, X., Qiu, P., et al. (2025). Depression and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational studies. Translational Psychiatry, 15, Article 463. https://doi.org/10.1038/s41398-025-03463-8
  7. First, M. B., Gaebel, W., Maj, M., et al. (2022). An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5-TR. World Psychiatry, 21(3), 356-387. https://doi.org/10.1002/wps.20969
  8. Fried, E. I., & Robinaugh, D. J. (2020). The 341,737 ways of qualifying for the melancholic specifier. The Lancet Psychiatry, 7(6), 479-480. https://doi.org/10.1016/S2215-0366(20)30169-3
  9. Furukawa, T. A., Maruo, K., Noma, H., et al. (2020). Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients. European Archives of Psychiatry and Clinical Neuroscience, 270(4), 507-516. https://doi.org/10.1007/s00406-020-01135-w
  10. Henssler, J., Schmidt, Y., Schmidt, U., et al. (2026). Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis. The Lancet Psychiatry, 13(1), 22-35. https://doi.org/10.1016/S2215-0366(25)00330-X
  11. Kaiser Permanente. (2024). Adult & Adolescent Depression Screening, Diagnosis, and Treatment Guidelines. Retrieved from https://wa.kaiserpermanente.org/static/pdf/public/guidelines/depression.pdf
  12. Lu, B., et al. (2024). Global burden of depression or depressive symptoms in children and adolescents: A systematic review and meta-analysis. Journal of Affective Disorders, 354, 602-615. https://doi.org/10.1016/j.jad.2024.03.033
  13. Mavranezouli, I., Megnin-Viggars, O., Pedder, H., et al. (2024). A systematic review and network meta-analysis of psychological, psychosocial, pharmacological, physical and combined treatments for adults with a new episode of depression. EClinicalMedicine, 75, 102780. https://doi.org/10.1016/j.eclinm.2024.102780
  14. Namiot, E. D., Smirnovová, D., Sokolov, A. V., et al. (2024). Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov. Translational Psychiatry, 14, 315. https://doi.org/10.1038/s41398-024-03031-6
  15. National Institute of Mental Health. (2023). Depression. Retrieved from https://www.nimh.nih.gov/health/topics/depression
  16. National Institute of Mental Health. (2023). Major Depression Statistics. Retrieved from https://www.nimh.nih.gov/health/statistics/major-depression
  17. Papakostas, G. I., Trivedi, M. H., Shelton, R. C., et al. (2024). Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Molecular Psychiatry, 29, 2287-2295. https://doi.org/10.1038/s41380-024-02468-x
  18. Parker, G. (2024). An Update on Melancholia. Psychiatric Times. Retrieved from https://www.psychiatrictimes.com/view/update-melancholia
  19. Parker, G., Fink, M., Shorter, E., et al. (2010). Issues for DSM-5: Whither melancholia? The case for its classification as a distinct mood disorder. The American Journal of Psychiatry, 167(7), 745-747. https://doi.org/10.1176/appi.ajp.2010.09101525
  20. Raja, S. M., Guptill, J. T., Mack, M., et al. (2024). A Phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers. Clinical Pharmacology & Therapeutics, 116(5), 1314-1324. https://doi.org/10.1002/cpt.3391
  21. Rucker, J. J., & Young, A. H. (2024). The development of psilocybin therapy for treatment-resistant depression: an update. BJPsych Bulletin, 48(1), 38-44. https://doi.org/10.1192/bjb.2023.25
  22. Singh, R., Volner, K., & Marlowe, D. (2023, July 17). Depression. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK430847/
  23. Substance Abuse and Mental Health Services Administration. (2024). Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/
  24. Valerio, M. P., Lomastro, J., Blasco, D., & Martino, D. J. (2023). Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STAR*D trial. Journal of Affective Disorders, 344, 532-539. https://doi.org/10.1016/j.jad.2023.10.106
  25. Zaninotto, L., Guglielmo, R., Calati, R., et al. (2019). Prognosis and improved outcomes in major depression: a review. Translational Psychiatry, 9, 127. https://doi.org/10.1038/s41398-019-0460-3